Lorcaserin Inhibit Glucose-Stimulated Insulin Secretion and Calcium Influx in Murine Pancreatic Islets
Lorcaserin is a serotonergic agonist specific to the 5-hydroxytryptamine 2c receptor (5-HT2CR) that is FDA approved for the long-term management of obesity with or without at least one weight-related comorbidity. Lorcaserin can restrain patients' appetite and improve insulin sensitivity and hyp...
Saved in:
Main Authors: | Muhan Jing (Author), Shanshan Wang (Author), Ding Li (Author), Zeyu Wang (Author), Ziwen Li (Author), Yichen Lu (Author), Tong Sun (Author), Chen Qiu (Author), Fang Chen (Author), Haijuan Yu (Author), Wei Zhang (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2021-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The use of lorcaserin in the management of obesity: a critical appraisal
by: Bo Bai, et al.
Published: (2010) -
Inhibition of Dectin-1 on Dendritic Cells Prevents Maturation and Prolongs Murine Islet Allograft Survival
by: Ren A, et al.
Published: (2021) -
Lorcaserin and metabolic disease: weight‐loss dependent and independent effects
by: H. Bays, et al.
Published: (2018) -
Lorcaserin improves glycemic control via a melanocortin neurocircuit
by: Luke K. Burke, et al.
Published: (2017) -
Effects of acute 3-h swimming exercise on insulin secretion capacity of pancreatic islets
by: Yudai Nonaka, et al.
Published: (2020)